

Melero et al., 1998 *Eur. J. Immunol.* 3:116), are contemplated for use according to the instant invention, as are polypeptides having at least 70% similarity (preferably a 70% identity) and more preferably 90% similarity (more preferably a 90% identity) to the reported polypeptides and still more preferably a 95% similarity (still more preferably a 95% identity) to the reported polypeptides and to portions of such polypeptides, wherein such portions of an SRA/IRAM polypeptide generally contain at least 30 amino acids and more preferably at least 50 amino acids.

In the claims:

Please amend claims 10 and 11 to read as follows:

10. (Amended) The composition of claim 9 wherein Her2/Neu comprises a polypeptide sequence selected from the group consisting of sequences set forth in GenBank Acc. Nos. X03363 (SEQ ID NO: 6), M17730 (SEQ ID NO: 8), and SEG_HUMHER20 (SEQ ID NO: 9).

11. (Amended) The composition of claim 9 wherein CD86/B7.2 comprises a polypeptide sequence selected from the group consisting of sequences set forth in GenBank Acc. Nos. AF099105, SEG_MMB72G (SEQ ID NOS: 11-15), U39466 (SEQ ID NOS: 16-20), U04343 (SEQ ID NO: 22), SEG_HSB725, L25606 (SEQ ID NO: 24), and L25259 (SEQ ID NO: 26).

REMARKS

The enclosed electronic and paper copies of the Sequence Listing include no new matter that goes beyond the original application as filed, but are supplied as requested by the Examiner. Furthermore, the above amendments, which merely direct the insertion of the Sequence Listing and insertion of sequence identifiers, include no matter that goes beyond the original application as filed. Applicants respectfully submit that the above-identified application is now in compliance with 37 C.F.R. §§ 1.821-1.825 and WIPO Standard ST. 25.